Pharmaceutical composition comprising factor VIII and neutral liposomes

• US 6,930,087 B2
• Filed: 12/26/2002
• Issued: 08/16/2005
• Est. Priority Date: 04/27/1998
• Status: Expired due to Term

• Current Assignee: Cantab Biopharmaceuticals Patents Limited
• Original Assignee: Opperbas Holding B.V.
• Inventors: Nur, Israel, Bar, Liliana, Baru, Moshe
• Primary Examiner(s): Weber, Jon
• Assistant Examiner(s): SCHNIZER, HOLLY G
• Application Number:
  US10/327,970
• Publication Number:
  US 20030134778A1
• Time in Patent Office: 964 Days
• Field of Search: 514/2, 514/802, 514/834, 424/450, 530/350, 530/380, 530/383
• US Class Current: 514/1.1
• CPC Class Codes: A61K 38/37 Factors VIII
• CPC Class Codes: A61K 9/1272 with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids with cholesterol as the only non-phosphatidyl surfactant A61K9/127; lipids as modifying agent A61K47/543
• CPC Class Codes: A61P 7/04 Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Abstract

A pharmaceutical composition for parenteral administration comprising a therapeutically effective amount of a protein or polypeptide and substantially neutral colloidal particles. The particles comprise approximately 1-20 mole percent of an amphipathic lipid derivatized with a biocompatible hydrophilic polymer which carriers substantially no net charge. The protein or polypeptide is capable of externally binding the colloidal particles, or is capable of binding polyethylene glycol, and is not encapsulated in the colloidal particles. A preferred protein is factor VIII, whose half-life is extended and which is protected from serum inhibitor antibodies by injecting it as a component of the composition.

Claims

1. A pharmaceutical composition for parenteral administration comprising a therapeutically effective amount of a therapeutic protein or polypeptide and substantially neutral colloidal particles, said particles comprising approximately 1-20 mole percent of an amphipathic lipid derivatized with a biocompatible hydrophilic polymer, said polymer carrying substantially no net charge,

wherein said protein or polypeptide is selected from the group consisting of:

(a) proteins or polypeptides capable of externally binding said colloidal particles; and

(b) proteins or polypeptides capable of binding polyethylene glycol,

wherein said protein or polypeptide is not encapsulated in said colloidal particles and is non-covalently bound thereto, and

wherein no therapeutic component is encapsulated in said colloidal particles.

2. The pharmaceutical composition of claim 1 wherein the colloidal particles have a mean particle diameter of about 0.05 to about 0.4 microns.

3. The pharmaceutical composition of claim 2 wherein the colloidal particles have mean particle diameter of approximately 0.1 microns.

4. The pharmaceutical composition of claim 1 wherein said amphipathic lipid is a phospholipid from natural or synthetic sources.

5. The pharmaceutical composition of claim 4 wherein said amphipathic lipid is phosphatidylethanolamine (PE).

6. The pharmaceutical composition of claim 1 wherein said biocompatible hydrophilic polymer is selected from the group consisting of polyalkylether, polylactic and polyglycolic acid families.

7. The pharmaceutical composition of claim 6 wherein said biocompatible hydrophilic polymer is polyethylene glycol.

8. The pharmaceutical composition of claim 7 wherein the polyethylene glycol has a molecular weight of about 1000 to about 5000 daltons.

9. The pharmaceutical composition of claim 8 wherein the polyethylene glycol has a molecular weight of approximately 2000 daltons.

10. The pharmaceutical composition of claim 1 wherein said colloidal particles further comprise a second amphipathic lipid obtained from either natural or synthetic sources.

11. The pharmaceutical composition of claim 10 wherein said second amphipathic lipid is phosphatidylcholine.

12. The pharmaceutical composition of claim 11, wherein the amphipathic lipid that is derivatized with a biocompatible hydrophilic polymer is phosphatidylethanolamine (PE).

13. A method of administering a therapeutically effective amount of a therapeutic protein or polypeptide to a patient, comprising parenteral administration of substantially neutral colloidal particles with said therapeutic protein or polypeptide non-covalently bound thereto, wherein:

(1) said colloidal particles comprise approximately 1-20 mole percent of an amphipathic lipid derivatized with a biocompatible hydrophilic polymer, said polymer carrying substantially no net charge;

(2) said protein or polypeptide is selected from the group consisting of;

(a) proteins or polypeptides capable of externally binding said colloidal particles; and

(b) proteins or polypeptides capable of binding polyethylene glycol,

(3) said protein or polypeptide is not encapsulated in said colloidal particles, and

(4) no therapeutic component is encapsulated in said colloidal particles.

14. The method of claim 13, wherein the colloidal particles have a mean particle diameter of about 0.05 to about 0.4 microns.

15. The method of claim 13, wherein said amphipathic lipid is a phospholipid from natural or synthetic sources.

16. The method of claim 13, wherein said colloidal particles further comprise a second amphipathic lipid obtained from either natural or synthetic sources.

17. The method of claim 16, wherein the amphipathic lipid that is derivatized with a biocompatible hydrophilic polymer is phosphatidylethanolamine (PE) and the second amphipathic lipid is phosphatidylcholine.